PROTAC RNF4 degrader-1

PROTAC RNF4 degrader-1 是一种 PROTAC 类 RNF4 降解剂(Kd = 64.5 nM),可通过泛素-蛋白酶体系统降解 RNF4,诱导 DNA 损伤和细胞凋亡 (apoptosis),在癌细胞中表现出抗增殖活性,并在小鼠模型中表现出抗肿瘤活性且无明显副作用,可用于肝细胞癌的研究(粉色:RNF4 配体 (MS-M39957);蓝色:VHL 配体 (MS-L68940);黑色:连接子)。
PROTAC RNF4 degrader-1
产品编号: MS-L61975 分子式: C47H52ClN5O7S 分子量: 866.46
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
25mg
询价
询价
50mg
询价
询价
100mg
询价
询价

产品描述

PROTAC RNF4 degrader-1 是一种 PROTAC 类 RNF4 降解剂(Kd = 64.5 nM),可通过泛素-蛋白酶体系统降解 RNF4,诱导 DNA 损伤和细胞凋亡 (apoptosis),在癌细胞中表现出抗增殖活性,并在小鼠模型中表现出抗肿瘤活性且无明显副作用,可用于肝细胞癌的研究(粉色:RNF4 配体 (MS-M39957);蓝色:VHL 配体 (MS-L68940);黑色:连接子)。

生物实验数据

生物活性 PROTAC RNF4 degrader-1 is a PROTAC-type RNF4 degrader (Kd = 64.5 nM) that degrades RNF4 via the ubiquitin-proteasome system, induces DNA damage and apoptosis (apoptosis), exhibits antiproliferative activity in cancer cells, and shows antitumor activity in mouse models without obvious side effects, and can be used for the study of hepatocellular carcinoma (pink: RNF4 ligand (MS-M39957); blue: VHL ligand (MS-L68940); black: linker).
IC50 & Target

VHL

 

RNF4

64.5 nM (Kd)

体外研究
(In Vitro)

PROTAC RNF4 degrader-1 (Compound RD12) (0.2-20 μM; 72 h) 可强效抑制人肝癌细胞 HepG2 的增殖,其 IC50 为 0.48 μM。
PROTAC RNF4 degrader-1 (0.1-10 μM; 6 h) 可在人肝癌细胞 HepG2 中诱导 RNF4 蛋白呈剂量依赖性降解。
PROTAC RNF4 degrader-1 (0-20 μM; 6 h) 可在人肝癌 Huh7 细胞中诱导 RNF4 蛋白的剂量依赖性降解,其 DC50 为 4.16 μM。
PROTAC RNF4 degrader-1 (5 μM; 6 h after 2 h pre-incubation with MG132) 介导的人肝癌细胞 HepG2 和 Huh7 中 RNF4 降解依赖于泛素-蛋白酶体系统,因为用蛋白酶体抑制剂 MG132 预处理可逆转 RNF4 的缺失。
PROTAC RNF4 degrader-1 (0.1-10 μM; 6 h) 可在人肝癌细胞 HepG2 和 Huh7 中诱导剂量依赖性的 DNA 损伤,该效应通过 γH2AX 水平的升高得到验证。
PROTAC RNF4 degrader-1 (0-20 μM; 6 h) 以剂量依赖方式在人肝癌 Huh7 细胞中上调 RNF4 底物蛋白 BRCA1 和 MDC1 的水平,该结果与 RNF4 降解的情况一致。
PROTAC RNF4 degrader-1 (serial two-fold dilutions; 30 min at room temperature) 可直接与重组 RNF4 蛋白结合,通过 MST 测得其 Kd 为 64.5 nM。
PROTAC RNF4 degrader-1 (10 μM; 6 h) 可在人肝癌 Huh7 细胞中选择性诱导 RNF4 降解,在鉴定出的 7483 种蛋白质中,仅 28 种出现显著下调。
PROTAC RNF4 degrader-1 (5 μM; 48 h) 可诱导 52.1%的人肝癌 Huh7 细胞发生凋亡。

Cell Viability Assay

Cell Line: HepG2 human hepatocellular carcinoma cells
Concentration: 0.2, 2, 20 μM
Incubation Time: 72 h
Result: Inhibited HepG2 cell proliferation with an IC50 of 0.48 ± 0.095 μM.

Western Blot Analysis

Cell Line: HepG2 human hepatocellular carcinoma cells
Concentration: 0.1, 1.25, 2.5, 5, 10 μM
Incubation Time: 6 h
Result: Induced dose-dependent degradation of RNF4 protein, with reduced RNF4 levels observed at all tested concentrations relative to untreated cells.

Western Blot Analysis

Cell Line: Huh7 human hepatocellular carcinoma cells
Concentration: 0.1, 1.25, 2.5, 5, 10 μM; 0, 0.625, 1.25, 2.5, 5, 10, 20 μM
Incubation Time: 6 h
Result: Induced dose-dependent degradation of RNF4 protein with a DC50 (degradation half-maximal concentration) of 4.16 ± 0.222 μM.

Western Blot Analysis

Cell Line: HepG2 and Huh7 human hepatocellular carcinoma cells
Concentration: 5 μM
Incubation Time: 6 h (after 2 h pre-incubation with MG132)
Result: Mediated RNF4 degradation that was rescued by pre-treatment with MG132, confirming dependency on the ubiquitin-proteasome system.

Western Blot Analysis

Cell Line: HepG2 and Huh7 human hepatocellular carcinoma cells
Concentration: 0.1, 1.25, 2.5, 5, 10 μM
Incubation Time: 6 h
Result: Induced dose-dependent increases in γH2AX levels (a marker of DNA double-strand breaks), with higher γH2AX expression observed at higher concentrations.

Western Blot Analysis

Cell Line: Huh7 human hepatocellular carcinoma cells
Concentration: 0, 5, 10, 20 μM
Incubation Time: 6 h
Result: Induced dose-dependent increases in BRCA1 and MDC1 protein levels (known substrates of RNF4), corresponding to reduced RNF4 levels.

Apoptosis Analysis

Cell Line: Huh7 human hepatocellular carcinoma cells
Concentration: 5 μM
Incubation Time: 48 h
Result: Induced apoptosis in 52.1% of Huh7 cells, as measured by Annexin V staining.
体内研究
(In Vivo)

PROTAC RNF4 degrader-1 (Compound RD12) (5-20 mg/kg;腹腔注射;每 2 天 1 次, 共 20 天) 可在 BALB/c 裸鼠中诱导显著的剂量依赖性肝癌肿瘤生长抑制,在 5 mg/kg 和 20 mg/kg 剂量下的抑制率分别为 58% 和 76%,且未产生可观察到的肝毒性或体重下降。

Animal Model: BALB/c nude (6-week-old, female, subcutaneously implanted with Huh7 cells)
Dosage: 5 mg/kg; 20 mg/kg
Administration: i.p.; once every two days; 20 days
Result: Achieved tumor growth inhibition rates of 58% at 5 mg/kg and 76% at 20 mg/kg compared to vehicle controls.
Induced significant degradation of RNF4 protein in tumor tissues at 5 mg/kg.
Caused no significant changes in mouse body weight.
Resulted in serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels similar to healthy controls, indicating no liver toxicity.

化学信息

分子量 866.46
分子式 C47H52ClN5O7S

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础